Saturday, December 3, 2022


Biotechnology News Magazine

Clinical Trial and Studies

Landmark EMPA-KIDNEY Trial Showed Significant Benefit of Jardiance® In Reducing Kidney Disease Progression or Cardiovascular Death by 28% vs. Placebo In People with Chronic...

EMPA-KIDNEY, the largest and broadest dedicated SGLT2 inhibitor trial in chronic kidney disease, provides new evidence for patients commonly seen in clinical practice

CTCs Isolated by the Parsortix System from Metastatic Breast Cancer Patients Can be Analysed by Multiple Downstream Techniques

This research highlights the ability to perform multiple downstream analyses on CTCs enriched using the Parsortix system.

Nuvalent Reports Preliminary Phase 1 Clinical Data from ARROS-1 Trial that Support Best-In-Class Potential of NVL-520 for Patients with ROS1-Positive NSCLC

ARROS-1 Phase 1/2 clinical trial of NVL-520 is for patients with advanced ROS1-positive non-small cell lung cancer and other solid tumors. These data will be presented today in the "New Drugs on the Horizon" oral plenary session at the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain.

Urovant Sciences Announces Publication of Pharmacokinetic Data on GEMTESA® (Vibegron 75mg) Administered as an Intact or Crushed Tablet

In the study, which involved healthy adults, GEMTESA was administered in a single 75-mg dose as an intact tablet vs. crushed and mixed with applesauce. The results suggest that crushing and administering vibegron with applesauce may be an appropriate consideration for patients with overactive bladder (OAB) and swallowing difficulties.

Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity

Steffen-Sebastian Bolz, M.D., Ph.D., Chief Scientific Officer of Aphaia Pharma. “APH-012 is designed to restore the intestinal hormone response, which is critical for weight control and metabolic balance.”

Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD...

The Phase 1 randomized, double blind, placebo-controlled trial is designed to demonstrate clinical safety and preliminary efficacy of the DYAI-100, COVID-19 recombinant protein RBD booster vaccine candidate.